An Introduction to Psoriasis
Psoriasis is a common, chronic inflammatory skin disease that can also affect the joints. Management involves topical and systemic medication, and phototherapy. In the past decade, increased understanding of the pathophysiology of autoimmune diseases has resulted in the development of systemic biologic therapies for moderate-to-severe disease, including inhibitors of tumour necrosis factor (TNF) α, and interleukins (IL)-12, IL-23 and IL-17A. Topical medications, including corticosteroids, vitamin D analogues, calcineurin inhibitors and keratolytics, remain the mainstay of treatment of mild-to-moderate disease. Therapies in the pipeline include tapinarof, a topical aryl hydrocarbon receptor modulating agent, and BMS-986165, an oral tyrosine kinase 2 inhibitor.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]
Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis
We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]
Linda Stein Gold, EADV 2020 – Roflumilast Cream in Chronic Plaque Psoriasis
We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258). Questions 1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06) 2. What is the mechanism […]
Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis
We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions What are the major unmet needs in the treatment […]
Tiago Torres, EADV 2020 – The IL-23 Pathway in Psoriasis
We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors. Questions Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!